13.01
0.32 (2.52%)
| Penutupan Terdahulu | 12.69 |
| Buka | 12.57 |
| Jumlah Dagangan | 532,404 |
| Purata Dagangan (3B) | 660,067 |
| Modal Pasaran | 905,195,456 |
| Harga / Jualan (P/S) | 12.94 |
| Harga / Buku (P/B) | 2.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 8 May 2025 |
| Margin Keuntungan | -160.80% |
| Margin Operasi (TTM) | -71.60% |
| EPS Cair (TTM) | -1.62 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 83.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.47% |
| Nisbah Semasa (MRQ) | 3.40 |
| Aliran Tunai Operasi (OCF TTM) | -110.04 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.16 M |
| Pulangan Atas Aset (ROA TTM) | -14.57% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.54% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Zymeworks Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.30 |
|
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.19% |
| % Dimiliki oleh Institusi | 102.09% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 30.00 (LifeSci Capital, 130.59%) | Beli |
| Median | 19.00 (46.04%) | |
| Rendah | 13.00 (HC Wainwright & Co., -0.08%) | Pegang |
| Purata | 20.67 (58.88%) | |
| Jumlah | 2 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 11.60 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| LifeSci Capital | 11 Mar 2025 | 30.00 (130.59%) | Beli | 11.70 |
| HC Wainwright & Co. | 10 Mar 2025 | 13.00 (-0.08%) | Pegang | 11.10 |
| Citigroup | 07 Mar 2025 | 19.00 (46.04%) | Beli | 12.00 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |